IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.089
AS - Asia 2.490
EU - Europa 867
SA - Sud America 434
AF - Africa 105
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 7.998
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.997
SG - Singapore 1.493
CN - Cina 461
BR - Brasile 356
VN - Vietnam 208
FI - Finlandia 178
IT - Italia 150
IE - Irlanda 110
DE - Germania 98
HK - Hong Kong 71
NG - Nigeria 65
IN - India 62
CA - Canada 61
GB - Regno Unito 58
NL - Olanda 54
FR - Francia 52
SE - Svezia 40
BD - Bangladesh 39
AR - Argentina 29
JP - Giappone 25
BE - Belgio 21
TR - Turchia 21
MX - Messico 20
IQ - Iraq 18
RU - Federazione Russa 17
PL - Polonia 16
CL - Cile 14
EC - Ecuador 14
CZ - Repubblica Ceca 12
UZ - Uzbekistan 12
ES - Italia 11
PK - Pakistan 10
AT - Austria 9
CO - Colombia 9
EG - Egitto 9
IL - Israele 9
ZA - Sudafrica 9
ID - Indonesia 8
SA - Arabia Saudita 8
UA - Ucraina 8
AE - Emirati Arabi Uniti 6
IR - Iran 6
PT - Portogallo 6
AZ - Azerbaigian 5
EU - Europa 5
KE - Kenya 5
MA - Marocco 5
AU - Australia 4
ET - Etiopia 4
KR - Corea 4
PE - Perù 4
VE - Venezuela 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KG - Kirghizistan 3
LT - Lituania 3
MY - Malesia 3
NP - Nepal 3
PH - Filippine 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AF - Afghanistan, Repubblica islamica di 2
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
HU - Ungheria 2
JM - Giamaica 2
LB - Libano 2
MD - Moldavia 2
NO - Norvegia 2
PY - Paraguay 2
RO - Romania 2
TN - Tunisia 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CH - Svizzera 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TV - Tuvalu 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.998
Salva come PNG Salva come JPEG
Città #
Singapore 676
Dallas 649
Chandler 516
Wilmington 409
Ashburn 300
The Dalles 199
Shanghai 181
Helsinki 177
San Jose 163
San Mateo 162
Beijing 135
Ann Arbor 131
Dublin 109
Boardman 97
New York 94
Lawrence 82
Princeton 82
Ho Chi Minh City 80
Leawood 77
Benin City 64
Hong Kong 54
Milan 52
Amsterdam 48
Hanoi 44
Paris 40
Phoenix 38
Los Angeles 33
Woodbridge 30
Seattle 27
São Paulo 27
Santa Clara 26
London 25
Fairfield 22
Pune 20
Toronto 20
Brussels 18
Montreal 18
Orem 16
Warsaw 16
San Diego 15
Munich 14
Haiphong 12
Rio de Janeiro 12
Porto Alegre 10
Tashkent 10
Baghdad 9
Brooklyn 9
Chennai 9
Kocaeli 9
Naples 9
Tokyo 9
Abbiategrasso 8
Assago 8
Dhaka 8
Frankfurt am Main 8
San Francisco 8
Andover 7
Atlanta 7
Council Bluffs 7
Da Nang 7
Jeddah 7
Norwalk 7
Salvador 7
Belo Horizonte 6
Brasília 6
Brno 6
Cairo 6
Chicago 6
Falkenstein 6
Guayaquil 6
Istanbul 6
Monmouth Junction 6
Raleigh 6
Redwood City 6
Biên Hòa 5
Bogotá 5
Columbus 5
Curitiba 5
Johannesburg 5
Manchester 5
Phủ Lý 5
Redmond 5
Ribeirão Preto 5
Umeda 5
Boston 4
Canoas 4
Denver 4
Falls Church 4
Houston 4
Hải Dương 4
Ludhiana 4
Mexico City 4
Nairobi 4
Porto 4
Reston 4
Rome 4
Shenzhen 4
Tai Kok Tsui 4
Winnipeg 4
Addis Ababa 3
Totale 5.352
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 154
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 136
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 119
Tivantinib for hepatocellular carcinoma 115
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 114
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 113
Biomarkers in Hepatocellular Carcinoma-Letter 109
COVID-19 and liver cancer clinical trials: not everything is lost 107
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 105
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 103
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 103
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 103
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 102
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 101
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 99
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 95
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 94
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 93
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 92
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 91
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 90
Cabozantinib for the treatment of hepatocellular carcinoma 88
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 88
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 88
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 88
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 85
Shaping the landscape of immune oncology in hepatocellular carcinoma 84
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 84
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 84
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 83
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 83
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 83
Reply to Y. Pointreau et al 83
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 83
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 82
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 82
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 81
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 80
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 79
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 79
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 78
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 78
Role of liver biopsy in hepatocellular carcinoma 78
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 77
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 77
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 76
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 76
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 76
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 75
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 75
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 75
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 74
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 74
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 72
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 72
Regorafenib for the treatment of unresectable hepatocellular carcinoma 72
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 71
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 71
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 71
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 71
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 70
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 69
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 69
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 68
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 68
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 66
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 66
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 64
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 64
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 63
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 63
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 62
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 60
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 60
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 60
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 59
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 59
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 59
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 58
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 58
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 58
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 57
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 56
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 56
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 55
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 54
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 54
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 53
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 53
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 53
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 52
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 51
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 51
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 50
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 50
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 49
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 48
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 48
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 46
OncoAlert round table discussions: The global COVID-19 experience 46
Totale 7.619
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.728
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.728
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021191 0 0 0 0 0 0 0 0 0 95 10 86
2021/2022553 15 8 2 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/20251.205 46 22 3 29 33 128 120 108 200 244 117 155
2025/20263.224 492 668 176 314 80 157 869 130 175 163 0 0
Totale 8.156